SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire & inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is trending strongly as its staking program sees significant adoption, with a substantial portion of tokens now locked, which the community views as a bullish indicator. Holders are rallying around its unique narrative as a 'pure belief asset' offering an alternative to traditional retirement plans, fueling widespread conviction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after securing FDA approval for NEREUS, marking the first new motion sickness treatment in decades. The community is highly focused on the drug's significant potential beyond motion sickness, particularly its ability to address nausea associated with GLP-1 weight loss medications, which could unlock a massive market. Investors are actively discussing whether the current valuation fully reflects this pivotal regulatory success and the company's broader pipeline.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing high volatility as investors await an overdue FDA decision on Relacorilant for Cushing's syndrome, a key PDUFA date that passed without official news. This has ignited intense community debate, with some highlighting strong GRACE trial data and the broader pipeline, while others express concern that the delay may indicate a Complete Response Letter amidst notable trading volume and market speculation.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

ProShares Short Bitcoin Strategy ETF ($BITI) is a focal point of market discussion as bearish sentiment on Bitcoin gains traction, with many anticipating a significant cryptocurrency pullback. The community is actively debating using inverse ETFs like BITI to either capitalize on or hedge against a potential Bitcoin correction, citing concerns over its speculative nature and "bubble" warnings from prominent investors. This reflects a prevailing view among some that Bitcoin's recent rally faces considerable downside risk.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending with strong anticipation for its upcoming earnings report, which is expected to highlight robust revenue growth and improving profitability driven by its high-margin Recorlev product. The community is increasingly optimistic about Recorlev's blockbuster potential and the advancement of the multi-blockbuster candidate XP-8121, leading to analyst target upgrades despite navigating recent price volatility.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is actively trending amid recent Ethereum staking announcements, which position it as a major ETH treasury, yet its stock performance is generating significant community discussion. Investors are currently debating ongoing share dilution and executive compensation plans against the company's ambitious Ethereum acquisition strategy, with many expressing frustration over the stock's disconnect from ETH's price movements and focusing on an upcoming critical shareholder vote.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Toro Company (The) (NYSE:TTC) Receives Consensus Rating of "Hold" from Brokerages

Shares of Toro Company (The) (NYSE:TTC - Get Free Report) have earned an average rating of "Hold" from the eight research firms that are currently covering the firm, MarketBeat reports. One research...

Traders Purchase Large Volume of Put Options on Toro (NYSE:TTC)

Toro Company (The) (NYSE:TTC - Get Free Report) saw some unusual options trading activity on Wednesday. Investors acquired 1,176 put options on the stock. This represents an increase of 1,709...

Zacks Research Downgrades Toro (NYSE:TTC) to Strong Sell

Zacks Research cut Toro from a "hold" rating to a "strong sell" rating in a research report on Monday...

Toro Q4 Earnings Call Highlights

Toro (NYSE:TTC) executives said the company closed fiscal 2025 with fourth-quarter sales and adjusted earnings per share ahead of internal expectations, pointing to continued momentum in underground...

Northland Capmk Issues Negative Forecast for Toro Earnings

Toro Company (The) (NYSE:TTC - Free Report) - Analysts at Northland Capmk reduced their Q1 2026 earnings per share estimates for shares of Toro in a report released on Thursday, December 18th...

What is Northland Capmk's Forecast for Toro Q2 Earnings?

Toro Company (The) (NYSE:TTC - Free Report) - Stock analysts at Northland Capmk reduced their Q2 2026 earnings per share (EPS) estimates for shares of Toro in a research report issued on Thursday...

Company News for Dec 18, 2025

Companies in The News Are: GIS,JBL,TTC,LEN

Toro (TTC) Q4 Earnings and Revenues Beat Estimates

Toro (TTC) delivered earnings and revenue surprises of +5.81% and +2.09%, respectively, for the quarter ended October 2025. Do the numbers hold clues to what lies ahead for the stock?

Toro (NYSE:TTC) Releases FY 2026 Earnings Guidance

Toro (NYSE:TTC) updated its FY 2026 earnings guidance. The company provided EPS guidance of 4.350-4.50 for the period, compared to the consensus estimate of 4.650...

Toro (NYSE:TTC) Issues Earnings Results, Beats Estimates By $0.05 EPS

Toro (NYSE:TTC - Get Free Report) issued its earnings results on Wednesday. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.86 by $0.05...

The Toro Co. engages in the provision of innovative solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. It operates through the following segments: Professional, Residential, and Other. The Professional segment includes designing professional turf maintenance, landscape and lighting, rental, specialty, and underground construction, snow and ice management, and agricultural products. The Residential segment is involved in marketing and selling products to homeowners through a variety of distribution channels including outdoor power equipment distributors and dealers, mass retailers, hardware retailers, home centers, and online and direct to end-users. The Other segment focuses on its wholly owned domestic distribution company, certain corporate activities, and the elimination of intersegment revenues and expenses. The company was founded by John Samuel Clapper and Henry Clay McCartney on July 10, 1914 and is headquartered in Bloomington, MN.

Current Price	$79.51
Prev Close	$79.13
Open	$78.86
Dividend Yield	2.03%
50-Day Moving Average	$73.50
Beta	0.77
Avg. Volume	684,519.05
PE Ratio	25.10

52-Week High	$87.46
52-Week Low	$62.34
Market Capitalization	$9.53B
EPS (Annual)	$3.17
Price to Book	5.36
Revenue Per Employee	$488,663.70
Enterprise Value/EBITDA	N/A

TTC
Toro Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TTC News

TTCToro Co.